ArticleMolecular pharmaceutics2019

Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes.

Jakub Hofman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.